InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations

BACKGROUND: Fibrinogen is the first qualified prognostic/predictive biomarker for exacerbations in patients with chronic obstructive pulmonary disease (COPD). The IMPACT trial investigated fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI and UMEC/VI in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Dave, Criner, Gerard J., Dransfield, Mark T., Halpin, David M. G., Han, MeiLan K., Lange, Peter, Lettis, Sally, Lipson, David A., Mannino, David, Martin, Neil, Martinez, Fernando J., Miller, Bruce E., Wise, Robert, Zhu, Chang-Qing, Lomas, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080358/
https://www.ncbi.nlm.nih.gov/pubmed/33910578
http://dx.doi.org/10.1186/s12931-021-01706-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080358/
https://www.ncbi.nlm.nih.gov/pubmed/33910578
http://dx.doi.org/10.1186/s12931-021-01706-y

Ejemplares similares